When MDUK was founded 60 years ago, very little was known about muscular dystrophy. From the initial funding of research into the underlying causes and sub-types of the condition to the first-ever clinical trial into long-term treatments using exon-skipping technology in the 2000s, great progress has been made thanks to the commitment of supporters and scientists alike.
Today, MDUK is still funding world-class research to advance treatments, such as gene therapy, while supporting clinical trials centres such as the MDUK Oxford University Neuromuscular Centre, the latest such centre to be launched. We live in an exciting time for research.
But our job isn’t done until we have effective cures and treatments. And that’s where gifts in Wills can make a real difference, helping fund the next generation of scientists finish what we’ve started together; so children born in the years to come can live free from the limitations of muscular dystrophy.
Approval for Spinraza in Scotland
We have heard today that, subject to sign-off, Spinraza
With myotonic dystrophy type 1 or mitochondrial disease
Company adopts MDUK as charity of the year 2019